Home › Funds › Frazier Life Sciences Management, L.P. › CYTK
Frazier Life Sciences Management, L.P. position in CYTK
CYTOKINETICS INC COM NEW · Health Care
Frazier Life Sciences Management, L.P. reported holding 1,159,879 shares of CYTK (CYTOKINETICS INC COM NEW) in its Q2 2026 13F filing — a position valued at US$98.8M, representing 2.15% of its reported portfolio and ranking #13 among its reported holdings. Frazier Life Sciences Management, L.P. has disclosed CYTK holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Frazier Life Sciences Management, L.P.'s CYTK position evolved
Frazier Life Sciences Management, L.P. first disclosed a stake in CYTK in Q2 2025 at 554,731 shares (US$18.3M). The position peaked in Q2 2026 at 1,159,879 shares, worth US$98.8M. Across 5 filings, Frazier Life Sciences Management, L.P. increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,159,879 shares valued at US$98.8M. Notable position changes include a 61% increase in Q3 2025 (shares rose 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 554.73K | $18.33M | New |
| Q3 2025 | 890.45K | $48.94M | Add |
| Q4 2025 | 934.64K | $59.39M | Add |
| Q1 2026 | 1.16M | $76.45M | Add |
| Q2 2026 | 1.16M | $98.81M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CYTK and 13F data
CYTK (CYTOKINETICS INC COM NEW) is a Health Care company. 51 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$425.9M), RTW INVESTMENTS, LP (US$243.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CYTK
- T. Rowe Price Investment Management, Inc. 18.72M sh · $1.59B · Q2 2026
- Avoro Capital Advisors LLC 5.00M sh · $425.95M · Q2 2026
- RTW INVESTMENTS, LP 2.86M sh · $243.81M · Q2 2026
- Polar Capital Holdings Plc 2.25M sh · $191.99M · Q2 2026
- Integral Health Asset Management, LLC 1.60M sh · $136.30M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.20M sh · $102.34M · Q2 2026
- Royalty Pharma Sub-Manager, LLC 980.39K sh · $83.52M · Q2 2026
- GW&K Investment Management, LLC 916.11K sh · $78.04M · Q2 2026
- Melqart Asset Management (UK) Ltd 767.52K sh · $65.39M · Q2 2026
- Siren, L.L.C. 758.95K sh · $64.66M · Q2 2026
- Foresite Capital Management IV, LLC 714.70K sh · $60.88M · Q2 2026
- Deep Track Capital, LP 700.00K sh · $59.63M · Q2 2026
More on Frazier Life Sciences Management, L.P.
FAQ
How long has Frazier Life Sciences Management, L.P. held CYTK?
Frazier Life Sciences Management, L.P. has disclosed CYTK holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
What is Frazier Life Sciences Management, L.P.'s current position in CYTK?
As of Q2 2026, Frazier Life Sciences Management, L.P. holds 1.16M shares of CYTK (CYTOKINETICS INC COM NEW), valued at $98.81M, representing 2.15% of its reported portfolio and ranking #13.
Has Frazier Life Sciences Management, L.P. been buying or selling CYTK?
In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. held unchanged its position in CYTK. The position peaked in Q2 2026 at 1.16M shares.
Which other funds hold CYTK?
Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, among 51 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.